Sanctura XR regulatory update

IDEV submitted an NDA to FDA for Sanctura XR to treat overactive bladder (OAB). IDEV hopes to launch the once-daily formulation of Sanctura trospium at the end of the third quarter of 2007. Esprit (Ea...